Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 24;14:731–744. doi: 10.2147/DDDT.S231916

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Hang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

ASK1 inhibition increased cholesterol efflux and cell proliferation, and reduced ROS production and cell apoptosis. An ASK1 inhibitor (GS-4997) was used to treat ox-LDL-induced endothelial cells. (A) A Cholesterol Efflux Assay Kit was used to analyze the levels of cholesterol efflux. (B) ABCA1 and ABCG1 expression were evaluated by Western blotting. (C) EdU staining was used to determine the viability of endothelial cells; magnification, ×100. (D) Cell apoptosis was determined by Annexin V FITC/PI double staining. (E) ROS levels were examined by flow cytometry. *P < 0.05, **P < 0.01 vs control group; ^#P < 0.05 vs ox-LDL group.